THE ROLE AND UTILITY OF CURRENT DIAGNOSTIC TESTS FOR ASTHMA IN THE ELDERLY
|
|
- Spencer Walsh
- 6 years ago
- Views:
Transcription
1 Journal of Experimental Medical & Surgical Research Cercetãri Experimentale & MedicoChirurgicale Year XVII Nr.3/2010 Pag JOURNAL Experimental Medical of Surgical R E S E A R C H THE ROLE AND UTILITY OF CURRENT DIAGNOSTIC TESTS FOR ASTHMA IN THE ELDERLY S. Macesanu 1 C. Vernic 2 R. Timar 1 C. Tudor 3 SUMMARY: Asthma (AB) is a common disorder in the general population, with a high prevalence, asthma diagnosis is difficult to establish in the elderly and very often it is overlooked. The aim of the study: the evaluation and comparison of modern diagnostic tests for asthma elderly. Material and methods: We evaluated 66 elderly patients over 60 years, with chronic cough, they were divided in 2 groups: 32 patients in group A, diagnosed with asthma and 34 patients in group B, with other chronic obstructive diseases. We used 5 methods of investigations: the best FEV1 by Spirometry, bronchodilation test (BDtest), exhaled nitric oxide measurement (FeNO) value, Airway hyperresponsiveness measuring(ahr), corticosteroids oral test, and best FEV1 value after corticosteroid inhaler treatment and statistical correlations between these tests. Results: spirometry and measurements FeNO were undertaken in all patients. In group A, FeNO values were significantly high in 19%, and mild in 59% of the cases, BDtest results were positive in 71.8% from group A. In those patients with negative results of BDtest, additional tests were undertaken: AHR test (positive in 12.5%), oral CStest (positive in 15.6%) and ICS inhaler after 3 monthstreatment (positive in 15.6%).In group A, the best FEV1(V1) and FeNO values were highly statistically significant (p<0.001). Conclusions: Bronchoreversibility was higher in group A, the FeNO value was helpful on diagnosis, and both tests were easy and cheap to apply on elderly. If FeNO is normal at baseline, it cannot be used in the diagnosis of asthma as single test and it should be well correlated with BDtest, AHR or CS test. Key Words: asthma, elderly, asthma diagnosis, modern tests for investigation. ROLUL ªI UTILITATEA METODELOR MODERNE DE DIAGNOSTIC ALE ASTMULUI BRONªIC LA VÂRSTNICI Received for publication: Revised: Rezumat: Astmul bronºic (AB) este o boalã cronicã frecventã în populaþia generalã, însã diagnosticul la vârstnici este dificil de efectuat ºi adesea omis.scopul studiului este de a evalua ºi compara metodele moderne de diagnostic al AB la vârstnici. Material ºi metode: Am evaluat un lot de 66 pacienþi cu tuse cronicã, divizaþi în 2 loturi: lot A au fost diagnosticaþi cu AB, lotul B, cu alte boli obstructive cronice. Sau folosit 5 metode curente de diagnostic al astmului: spirometrie forþatã (cel mai bun FEV1), test de bronhodilatare inhalator (BDtest), mãsurarea hiperresponsivitãþii bronºice cu metacholinã (AHR), mãsurarea valorii FeNO din aerul exhalat, test cu corticosteroizi oral(csoral) ºi corticosteroizi inhalator(ics) timp de 3 luni ºi corelaþii statistice între metodele utilizate.rezultate: la toþi pacienþii sa efectuat spirometrie fortaþã ºi dozarea FeNO.In lotul A, 19% valori FeNO crescute, 59% prezente dar uºoare iar tesul BD a fost pozitiv la 71,8% cazuri.la pacienþii cu BDtest negativ sau efectuat teste suplimenatare:cu metacholinã(12,5% pozitivi),test cu corticosteroizi orali(15,6% pozitivi), test cu ICS 3 luni (15,6% pozitivi). In lotul A, au avut corelaþie semnificativã statistic testele FeNOFEV1(V1), (p<0,001). Concluzii: bronhoreversibilitatea este demonstratã la un numãr mare de pacienþi din lotul A, dozarea FeNO ajutã la diagnosticarea AB, ambele teste sunt accesibile ºi uºor de efectuat la vârstnici. Dacã valoarea FeNO este intermediarã iniþial, nu trebuie consideratã ca singurul marker pozitiv al inflamaþiei bronºice, ci trebuie corelatã cu celelalte teste, AHR sau CS test. Cuvintecheie: astm bronºic, vârstnici, teste diagnostice. 1. Emergency County Hospital, Timisoara; 2 University of Medicine and Pharmacy V Babes, Timisoara; 3 University of Medicine and Pharmacy V Babes, Timisoara Correspondence to: Simona Orieta Mãceºanu, Ambulatory I, Emergency County Hospital, Timiºoara, macesanusimona@yahoo.com 194
2 INTRODUCTION Asthma is a common disorder in the general population with an overall prevalence of up to 7 8%.(1) Despite this high prevalence, asthma diagnosis is difficult in the elderly and very often it is overlooked. At elderly asthmatics patients, the diagnostic and therapy problems are inadequately treated. The diagnosis of asthma was based on patient history and clinical examination, in addition to objective evidence of specific pulmonary function testing, with the demonstration of reversible airway obstruction, but there are unique problems in performing these tests in older patients and in their often wrong interpretation.(2) The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guide criteria show that a 70% ratio of FEV1/FVC as value for the airway obstruction, may not necessarily be true in older people and can result in overdiagnosis of obstructive lung disease in older patients. Severity of pulmonary function decline in elderly people with asthma is multifactorial: clinical condition, age, time before diagnosis, history of cigarette smoking and clinical phenotype, all can contribute to disease severity. When there are diagnostic difficulties, objective tests are needed. Abnormal spirometry at diagnosis of asthma in older patients is a common phenomenon, and relationship between delay in diagnosis and commencement of appropriate therapy, is likely due to nonspecific presentation of symptoms and the diagnostic difficulties highlighted above.(3) Spirometry has been used as a gold standard in diagnosis and monitoring treatment in asthma. Forced Expiratory Volume in 1 second (FEV1) begins to decline from approximately the middle of the third decade at the rate approximately 30 ml/year for men and 25 ml/year for women. Most longitudinal studies suggest an accelerated decline in FEV1 (to 38 ml/year).(4) Definitions of the bronchial obstructive reversibility, controversial in COPD, are more clearly for asthma. An improvement in FEV1 of at least 12% after administration of bronchodilators is accepted for positive AB diagnosis.(5) In asthmatics elderly, a negative bronchodilator response to a shortacting beta2 agonist does not rule out a diagnosis of asthma because they have a fixed airflow obstruction from many causes. Often, treatment with ICS over time will improve lung function and, when documented by spirometry, a diagnosis of asthma can be confirmed.6 Differentiation of COPD in order to perform the test with oral cortisone ( mg/kg bw/day), for 714 days. Because of possible CS oral side effects, are used recently, ICS test for 6 weeks3 months, it s simple test, without possible side effects.7 In last years, measuring exhaled nitric oxide (FeNO) has been proposed as a marker of airway inflammation, an easier and cheaper method, but is less accessible. Routine use of FeNO for the diagnosis and management of asthma requires standardization and agreed reference ranges, which vary as a function of age and height. Exhaled NO is increased during exacerbations of asthma, and reduced in subjects taking inhaled corticosteroids.(8) Airway hyperresponsiveness (AHR), a specific feature of asthma, is considered to be related to airway inflammation and are changes of severity after ICS treatment. AHR may be measured using challenge tests with direct agonists such as histamine or metacholina.9 MATERIAL AND METHODS The authors have proposed the investigation of 64 elderly patients with chronic cough, using modern and available diagnostic tests for asthma, using functional criteria for asthma diagnosis and the markers of airway inflammation. Between 2007 and 2009 we selected for our study from the physician s office in the Ambulatory Care of Emergency County Hospital, Timisoara, Medicali s Clinic and from Clinic Hospital Timisoara sixtysix consecutive elderly patients, over 60 years of age. The patients were divided into two groups, Group A included 32 asthmatic patients and Group B included 34 patients with other chronic respiratory diseases. Patient s main symptoms was chronic cough, history of cough lasting over 6 months; moreover patients were recently diagnosed with asthma, and had no previous treatment with steroids or antileukotriens. As exclusion criteria were febrile respiratory tract infection within 4 weeks, incompliance, severe respiratory or cardiovascular failure, alcoholism and active tuberculosis. Protocol: 1. Evaluation of basal pulmonary function with spirometry, using easytach spirometer with color screen (KOKO Legend model). 2. Bronchodilation test (BDtest), with measurement the best FEV1 out before and 15 min after short action beta2agonists inhalation (salbutamolum 400ìg or 195
3 Ipratropium bromide, 20 ìg x 24 doses), according to the American Thoracic Society guidelines. 3. Evaluation of bronchial responsiveness (AHR): Bronchial challenge tests to Methacholine if FEV1>80%, (PC20, methacholine concentration inducing 20% fall in FEV1), on corticosteroid naive patients. 4. Measurement fraction of nitric oxide (FeNO) in exhaled air with electrochimical analyzer (NIOX MINO ), noninvasive, quick and easy FeNO measurement, repeatable and reproducible results, detection limit: 5 ppb, interpretable value 2550 ppb, significant value over 50 ppb. 5. Oral corticosteroid test (CStest) with Prednisone 0.4mg /kg bw/day, during 7 days, and repetable the best FEV1 (positive test post bronchodilation over 500ml). 6. In dynamics, best FEV1 after 3 months therapy with the CS inhaler treatment (for patients nonresponsiveness to other tests), using a dose of budesonide µg/day or beclomethasone. The Table.1. Baseline characteristics of the study: Associated respiratory comorbidities inhaled corticosteroids test is considered positive when FEV1 value increases with 500ml, before and after administration of beta2 agonists. Data were analyzed with Pearson s correlation coefficient (r), chisquare test, unpaired ttest and test of linear regression. According to current asthma management guidelines, the level of severity and adjustment of antiinflammatory asthma treatment are guided by symptoms and lung function.(10) RESULTS Classification of asthma control level was performed according to guidelines GAMA (11), show that most patients had forms of partially controlled or uncontrolled disease at initial visit (V1), before treatment CS inhaler. Associated respiratory comorbidities in the both groups had higher prevalence, especially smoking history, table 1. Group A Group B P value Allergic rhinitis 25% Chronic respiratory failure 9.3% 32.35% p = S TB disabling 6.2% 11.7% p = NS Smoking current history 34.3% 76.47% p = ES Bronchiectasis 3.1% 14.7% p = NS COPD 79.4% Chronic bronchitis 26.4% Best FEV1 initial visit(v1) 66.69± ± p = S Best FEV1 post BDtest 71.53± ± p = FS Functional test performed BD test(beta2 agonists) Metacholine test (AHR) Oral corticosteroids(cstest) Measuring FeNO Best FEV1 after 3months ICS Levels of asthma control in V1 AB uncontrolled AB partially controlled AB controlled FeNO value FeNO significant (over 50ppb) FeNO present, but mild(2550ppb) FeNO unlikely( under 24ppb) 12.5% 15.6% 15.6% 28% 47% 25% 19% 59% 22% Negative 14.47% p= S p<0.001 ES 196
4 Fig.1 FeNO value Value NO Fig.1 FeNO value in group A. The value of NO test should be interpreted in clinical context and it may have a high diagnostic value (Fig.1).In group B, all the patients had insignificant FeNO value. The bronchodilation test was negative in all patients from group B, with low variation below 12 % of predicted FEV1, statistically insignificant. In those patients who had negative BDtest, AHRtest was performed, which had hit 4 of 7 patients. Among patients with uncertain positive result BDtest, or We calculated Pearson Correlation Coefficients (r), and we found a strong inverse correlation value between NO FEV1 (V1), (r = 0.614, p < 0.001), which was highly statistically significant, in group A, Fig 3. We founded low correlation between the values FEV1BDtest and FeNO valuesstatistically insignificant and also, moderate correlationstatistically significant, between AHR valuesfev1(v1), (r=0.383, p= 0.031), in group A. Fig.2.Positive tests distribution in group A. negative/not taken AHR test; an additional CS oral test was positive in 5 patients. Distribution tests with positive results obtained in group A (Fig.2). Our evaluations were predictable, % of the asthmatic patients who had fixed airflow obstruction, after 3 months treatment with CSI+BDLA (medication was recommended as guide GAMA 2008 )(11), achieved normal FEV1. In group B, CStest was performed in patients with uncertain diagnosis of asthma or COPD (41.47 %), and the results were negative in all patients. The average FEV1 (V1) value of group A (66.69± ) compared with FEV1 (V1) value of group B (57.62 ± ), was statistically significantly increased (p<0.012). Comparing the average FEV1 value after BDtest between 2 groups, we found that FEV1 value from group A was statistically significantly higher (p<0.0006). Comparing the FeNO value between the two groups, FeNO value in elderly asthmatics was highly statistically significantly increased (p<0.001). 197
5 Value NO FEV1 (V1) DISCUSSIONS Fig.3. Correlation between FeNO value and FEV1(V1) in group A. In subjects thought to be at risk, spirometry should be obtained first. With this evidence, in the case of patients without airway obstruction but still at risk, methacholine challenge testing can be used to further refine the probability that asthma is present. However, this test is not sensitive or specific for asthma, and as a measure of airway hyperresponsiveness, it may not be predictably accurate in the elderly population (may have positive results also in other diseases), but in correlation with other investigation methods may be helpful, if this test it is expensive.(12) Many respiratory comorbidities were associated in elderly, but the differential diagnosis with COPD was the main problem at elderly patients with chronic cough.(13) The impact of smokinginduced lowering of pulmonary function might explain a lower FEV1 in some older smoking patients. In fact, the actual prevalence of current smokers in our study it s higher, smoking cessation is a method to decrease FEV1 decline.(14) The data had reported increase level NO in other airway diseases, the use of FeNO as only asthma diagnosis it is insufficient but is useful. In some asthmatic groups of patients (with main symptom the cough), FeNO could be normal, using the hypothesis: bronchial epithelial damage can lead to decreased synthesis of NO in the airways. Also in smokers FeNO value may was low, and this explain the lower values of FeNO in patients with chronic obstructive diseases and smoking (from group 2), our results was comparable with data.(1516 ) CONCLUSIONS 1. The positive AHR test is a better marker of disease and useful too, when the forced spirometry and BDtest is normal. 2. If FeNO is normal at baseline, it cannot be used in the diagnosis of asthma as a single marker of airway inflammation, and should be well correlated with BDtest, AHR or CS test, if possible. 3. Our records show that BDtest (with positive test) and FeNO measurement are accessible, rapid and inexpensive diagnostic tests for AB in the elderly. 4. Study shows that if these modern methods of investigation for asthma diagnosis have been available and two out of five tests have been positive, they are sufficient to establish an accurate asthma diagnosis and to make a differential diagnosis easier. REFERENCES: 1. Evans R, Mullaly DI, Wilson RW, et al. National trends in the morbidity and mortality of asthma in the US.Chest.1987;91: Chotirmall SH, Watts M, et al. Diagnosis and Management of Asthma in Older Adults. JAGS. 2009;57: Burrows B, Lebowitz MD, Barbee RA, et al. Findings before diagnoses of asthma among the elderly in a longitudinal study of a general population sample. J Allergy Clin Immunol.1991;88: Crapo RO. The ageing lung. Pulmonary Disease in the Elderly Patient.1993;63: American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis.1991;144: Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States, NHNE Survey , Arch Intern Med. 2000;160: Tudorache V, Mihaiescu T, Mihaltan F. Pulmonary elderly pathology. Ed.Didactica. 2004:
6 8. Junpei S, Suguru S. et al. OffLine Fractional Exhaled Nitric Oxide Measurement Is Useful to Screen Allergic Airway Inflammation in an Adult Population, J of Asthma. 2007;44: Leuppi JD, Salome CM, Jenkins CR, et al. Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled Corticosteroids. Am. J. Respir. Crit. Care Med. 2001;163(2): GINA Report, The Global Strategy for Asthma Management and Prevention. Updated guide. dec GAMA, Update guide for asthma management, Romanian Society of Pneumology Cuttitta G, Cibella F, Bellia V, et al. Changes in FVC during methacholineinduced bronchoconstriction in elderly patients with asthma: bronchial hyperresponsiveness and aging. Chest. 2001;119(6): Fabbri L, Romagnoli M, Corbetta L et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167: Quadrelli SA, Roncoroni AJ. Is Asthma in the Elderly Really Different? Respiration. 1998;65: Improving Diagnosis and Management of Asthma through FeNO Measurement. [Online] Available from URL: Silkoff PE, et al. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, Am J Respir Crit Care Med. 2005;171:
This is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationImportance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma
Original Article Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma Feng-Jia Chen, Huai Liao, Xin-Yan Huang, Can-Mao Xie Department of Respiratory
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationMethacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationComparison of exhaled nitric oxide measurements between NIOX MINO â electrochemical and Ecomedics chemiluminescence analyzer
Respiratory Medicine (2008) 102, 1667e1671 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed SHORT COMMUNICATION Comparison of exhaled nitric oxide measurements between
More informationASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 ASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT Dana ALEXANDRESCU 1 Abstract: The author of
More informationKEY WORDS airflow limitation, airway hyperresponsiveness, airway inflammation, airway lability, peak expiratory flow rate
Allergology International. 2013;62:343-349 DOI: 10.2332 allergolint.13-oa-0543 ORIGINAL ARTICLE Stratifying a Risk for an Increased Variation of Airway Caliber among the Clinically Stable Asthma Atsushi
More informationExhaled Biomarkers Asthma & COPD. AS Paul DM Seminar 30 March 07
Exhaled Biomarkers Asthma & COPD AS Paul DM Seminar 30 March 07 Introduction Diagnosis and course of COPD/Asthma Clinical information Pulmonary function tests Arterial blood gases Chest X-raysX No direct
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationAsma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli
Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre 2015 Overlap asma BPCO Dr. Marco Contoli Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara (Sept.
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: MEASUREMENT OF EXHALED MARKERS OF AIRWAY INFLAMMATION IN PATIENTS WITH ASTHMA POLICY NUMBER: 2.01.41 CATEGORY: Technology Assessment EFFECTIVE DATE: 04/15/04 REVISED DATE: 02/17/05,
More informationClinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT
Clinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT Disclosures I am an employee of Circassia Pharmaceuticals. Objectives Nitric Oxide Inflammation in Asthma Phenotyping Personalized Medicine
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationOptimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?
Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate
More informationTHE COPD-ASTHMA OVERLAP SYNDROME
THE COPD-ASTHMA OVERLAP SYNDROME NICOLA A. HANANIA, MD, MS, FRCP(C), FCCP, FACP ASSOCIATE PROFESSOR OF MEDICINE DIRECTOR OF ASTHMA & COPD CLINICAL RESEARCH CENTER BAYLOR COLLEGE OF MEDICINE HOUSTON, TX
More informationExhaled Nitric Oxide Today s Asthma Biomarker. Richard F. Lavi, MD FAAAAI FAAP
Exhaled Nitric Oxide Today s Asthma Biomarker Richard F. Lavi, MD FAAAAI FAAP Objectives Describe exhaled nitric oxide physiology and pathophysiology Review the current literature regarding exhaled nitric
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationHow to distinguish between uncontrolled and severe asthma
How to distinguish between uncontrolled and severe asthma Watch patient using their inhaler. Discuss adherence and barriers to use Compare inhaler technique with a devicespecific checklist, and correct
More informationSPIROMETRY TECHNIQUE. Jim Reid New Zealand
Jim Reid New Zealand The Basics Jim Reid Spirometry measures airflow and lung volumes, and is the preferred lung function test in COPD. By measuring reversibility of obstruction, it is also diagnostic
More informationAsthma: diagnosis and monitoring
Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Measurement of Exhaled Nitric Oxide and Page 1 of 18 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationFeNO-based asthma management results in faster improvement of airway hyperresponsiveness
ORIGINAL ARTICLE ASTHMA FeNO-based asthma management results in faster improvement of airway hyperresponsiveness Katrine Feldballe Bernholm 1, Anne-Sophie Homøe 1, Howraman Meteran 1, Camilla Bjørn Jensen
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationYuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh
2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationMeasurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders
Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders Policy Number: 2.01.61 Last Review: 9/2018 Origination: 2/2007 Next Review: 3/2019
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationALLERGY IN RESPIRATORY AIRWAY DISEASE AND
Allergy in Respiratory Airway Disease and Beyond Unit No. 2 differentiating asthma from chronic obstructive pulmonary disease Dr Lee Pyng ABSTRACT Asthma and chronic obstructive pulmonary disease (COPD)
More informationThe Clinical Phenotype of Asthma in Obesity. Anne Dixon, MA, BM, BCh
The Clinical Phenotype of Asthma in Obesity Anne Dixon, MA, BM, BCh Outline Epidemiology How obesity effects clinical phenotype Phenotypes of asthma in the obese Obesity Trends* Among U.S. Adults BRFSS,
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationBronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL
Bronchial asthma MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL DEFINITION ASTHMA BRONCHIALE = Asthma is a chronic inflammatory disorder of the airways in which
More informationThe impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease
The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease Dr. Lo Iek Long Department of Respiratory Medicine C.H.C.S.J. Chronic Obstructive Pulmonary Disease (COPD)
More informationPeak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics
ORIGINAL ARTICLE Peak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics Kazuto Matsunaga, Masae Kanda, Atsushi Hayata,
More informationA diagnosis of asthma is made on the basis of compatible
383 ASTHMA Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests N Berkman, A Avital, R Breuer, E Bardach, C Springer, S Godfrey... See end of article for authors
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is
More informationThe Aging Lung. Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI
The Aging Lung Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI Is the respiratory system of the elderly different when compared to younger age groups? Respiratory Changes
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationMeasurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders Policy Number: 2.01.61 Last Review: 9/2014 Origination: 2/2007
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationMeasure breath nitric oxide for airway inflammation with the NObreath FeNO monitor
Measure breath nitric oxide for airway inflammation with the NObreath FeNO monitor British technology Improving asthma management, one breath at a time. www.bedfont.com w on 01622 851122 or email ask@bedfont.com
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationLung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationWhich asthma patient has allergic airway inflammation?
Which asthma patient has allergic airway inflammation? C o n t r o l l i n g A l l e r g i c A s t h m a Several underlying diseases can present symptoms similar to asthma. Therefore, a correct diagnos
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.
Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationCOPD: Genomic Biomarker Status and Challenge Scoring
COPD: Genomic Biomarker Status and Challenge Scoring Julia Hoeng, PMI R&D Raquel Norel, IBM Research 3 rd October 2012 COPD: Genomic Biomarker Status Julia Hoeng, Ph.D. Philip Morris International, Research
More informationBronchial Provocation Results: What Does It Mean?
Bronchial Provocation Results: What Does It Mean? Greg King 1 Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards 2065 2 Woolcock Institute of Medical Research and Sydney Medical
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationSpirometry: Introduction
Spirometry: Introduction Dr. Badri Paudel 1 2 GMC Spirometry Spirometry is a method of assessing lung function by measuring the volume of air the patient can expel from the lungs after a maximal expiration.
More informationSCREENING AND PREVENTION
These protocols are designed to implement standard guidelines, based on the best evidence, that provide a consistent clinical experience for AHC II Integrated Clinical Delivery Network patients and allow
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More information#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA
Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker
More informationAsthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of
More informationAsthma Update I have no professional or personal financial conflicts of interest to disclose.
Asthma Update 2018 Disclosures Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center I have
More informationAsthma Update Jennifer W. McCallister, MD, FACP, FCCP
Asthma Update 2018 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center Disclosures I have
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationAsthma treatment ideally achieves a steady. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma
Eur Respir J 2010; 35: 1221 1227 DOI: 10.1183/09031936.00118809 CopyrightßERS 2010 Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma L.A. Pérez-de-Llano*, F. Carballada #,
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationPulmonary Function Testing
In the Clinic Pulmonary Function Testing Hawa Edriss MD, Gilbert Berdine MD The term PFT encompasses three different measures of lung function: spirometry, lung volumes, and diffusion capacity. In this
More information